NEUROMODULATION
hamburger
ST. JUDE MEDICAL INFINITY™ DBS SYSTEM
product photo

INSPIRED BY PATIENTS, ENGINEERED FOR PHYSICIANS

The St. Jude Medical Infinity™ DBS System is proven to enable you to provide patients with streamlined, personalized deep brain stimulation (DBS) therapy that gives them back control of their Parkinson's disease or essential tremor symptoms.1,2

AN ADVANCED DBS PLATFORM

The St. Jude Medical Infinity™ DBS System combines innovative directional lead technology and a wireless platform with enhanced patient comfort letting you offer patients the very latest in DBS treatment.

DIRECTIONAL LEAD TECHNOLOGY EMPOWERS PRECISION

The St. Jude Medical Infinity™ DBS System includes segmented, directional lead technology designed to steer current towards desired structural areas to optimize patient outcomes and limit side effects.3

A WIRELESS IOS* SOFTWARE MOBILE PLATFORM

The St. Jude Medical Infinity™ DBS system features an industry-leading DBS iOS* software wireless platform. It's designed to streamline therapy management for a discreet, personalized experience for your patients. It is also uses an iOS* software platform and Apple* mobile digital devices as programming platforms.

ENHANCED COMFORT FOR YOUR PATIENTS

The St. Jude Medical Infinity™ DBS system’s sleek, durable design helps make DBS therapy comfortable for your patients.

INVESTING IN INNOVATION … TODAY AND TOMORROW

The St. Jude Medical Infinity™ DBS IPG is part of our deep brain stimulation portfolio. Our vision is to transform the management of movement disorders through innovations in symptom control and patient experience — and through investments in clinical research. Read about the work we’re doing.

Access our product manuals and instructions for use.

GET STARTED

Stay up to date with our latest product advisories.

READ MORE

CLINICALLY PROVEN DBS THERAPY TECHNOLOGY

Our clinical studies support the use of St. Jude Medical Infinity™ DBS System as an effective way to control symptoms in patients with Parkinson’s disease and essential tremor.1,2 We also invest in partnerships to improve the patient experience by combining clinical research with new technologies to drive innovation while improving efficacy.

PARKINSON’S DISEASE STUDY RESULTS

For patients with Parkinson’s disease, St. Jude Medical™ DBS therapy is clinically proven to provide a better quality of life than with medication alone:

  • Proven to improve quality of life1
  • Proven to give patients good quality “on time” for the majority of their waking hours4

INCREASE IN “ON TIME”

Our DBS therapy improves “on time” without dyskinesias or with nonbothersome dyskinesias and sustains improvement up to 12 months in patients with Parkinson’s disease.1Line graph showing parkinsons increase chart

The primary endpoint was met at 3 months with a statistically significant (p=0.003) improvement in “on time” without dyskinesias or with nonbothersome dyskinesias for the stimulation group (4.27 hours of “on time”) compared to the control group (1.77 hours of “on time”).1

IMPROVED QUALITY OF LIFE

The stimulation group improved Parkinson’s symptoms through one year as measured by Unified Parkinson’s Disease Rating Scale (UPDRS) activities of daily living, motor examination, complications and total score.1

Bar graph showing improved symptoms during one year chart

Stimulation provided significant improvement in the total quality of life score (as measured by the PDQ-36) as well as in the individual components: mobility, activities of daily living, functional well-being and stigma.1

GLOBAL OUTCOME MEASURES AT 90 DAYS

The stimulation group demonstrated significant improvement in disability assessment as measured by the Global Outcome Measures compared to the control group (at 90 days).†,1

Charts showing patient assessment results graphic

ESSENTIAL TREMOR STUDY RESULTS

Therapy using a St. Jude Medical Infinity™ DBS system demonstrates a significant improvement in patient qualify of life after one year of stimulation as measured by the Quality of Life in Essential Tremor (QUEST) and the Short Form 36 (SF-36):

  • 9 out of 10 patients with essential tremor were satisfied or very satisfied with the St. Jude Medical Infinity™ DBS system’s ability to control their symptoms.2
  • 98% of patients with essential tremor would recommend a St. Jude Medical Infinity™ DBS system to someone dealing with tremor.2

Access our MRI ready resources and learn about our scan parameters.

 

Reorder Number Dimensions (H x W x T, cm) Weight (g) Volume (cc) Battery
6660ANS 5.55 x 4.95 x 1.34 48.9 30.4 5.3
6661ANS 5.55 x 4.95 x 1.34 48.9 30.4 5.3
6662ANS 6.68 x 5.02 x 1.35 58.3 38.6 7.5
6663ANS 6.68 x 5.02 x 1.35 58.3 38.6 7.5

QUESTIONS ABOUT REIMBURSEMENT?

We’ve got the answers you’re looking for.


References:

* iOS is a trademark of Cisco Technology, Inc. Apple is a trademark of Apple, Inc. †Global Outcomes Measure is of a self-rated single item questionnaire that measures a global assessment of the patient's quality of life, the caregiver's interpretation of the patient's quality of life as well as the examiner's interpretation of the patient's quality of life.

1. St. Jude Medical. (2012). Data on file, Parkinson's Disease Study Report C-04-01.

2. St. Jude Medical. (2014). Data on file, Tremor Study Final Report C-04-02.

3. St. Jude Medical. SJM Infinity Clinical Compendium SJM-INF-0416-0046a.

4. Okun M, Gallo BV, Mandybur G, Jagid J, Foote KD, Revilla FJ, Tagliati M. Subthalamic deep brain stimulation with a constant-current device in Parkinson’s disease: An open-label randomized controlled trial. The Lancet Neurology. 2012. 11(2), 140-149.

 

 

IMPORTANT SAFETY INFORMATION

Deep Brain Stimulation

Prescription and Safety Information

Read this section to gather important prescription and safety information.

Intended Use

This neurostimulation system is designed to deliver low-intensity electrical impulses to nerve structures. The system is intended to be used with leads and associated extensions that are compatible with the system.

Indications for Use

This neurostimulation system is indicated for unilateral or bilateral stimulation of the thalamus, internal globus pallidus (GPi), or subthalamic nucleus (STN) in patients with levodopa-responsive Parkinson’s disease.

Contraindications

Implantation of this neurostimulation system is contraindicated for the following:

  • Patients for whom test stimulation is unsuccessful.
  • Patients who are unable to properly operate the system.

The following procedures are contraindicated for patients that have been implanted with this device:

Diathermy therapy. Do not use short-wave diathermy, microwave diathermy, or therapeutic ultrasound diathermy (all now referred to as diathermy) on patients implanted with a neurostimulation system. Energy from diathermy can be transferred through the implanted system and can cause tissue damage at the location of the implanted electrodes, resulting in a severe injury or death. Diathermy is further prohibited because it may also damage the neurostimulation system components. This damage could result in loss of therapy, requiring additional surgery for system replacement. Injury or damage can occur during diathermy treatment whether the neurostimulation system is turned on or off. All patients are advised to inform their healthcare professional that they should not be exposed to diathermy treatment.

Magnetic resonance imaging (MRI). Do not use a full body radiofrequency (RF) coil or other extremity coils on patients implanted with a neurostimulation system. Because energy from MRI can be transferred through the implanted system, the potential for heat generation at the location of the electrodes exists. This isolated temperature rise may cause tissue damage at the location of the implanted electrodes, possibly resulting in severe injury or death. Injury can occur during MRI treatment whether the neurostimulation system is turned on or off. All patients are advised to inform their healthcare professional that they should not be exposed to MRI.

Warnings

The following warnings apply to these components.

Poor surgical risks. Neurostimulation should not be used on patients who are poor surgical risks or patients with multiple illnesses or active general infections.

Electrosurgery. To avoid harming the patient or damaging the neurostimulation system, do not use monopolar electrosurgery devices on patients with implanted neurostimulation systems. Before using an electrosurgery device, place the device in Surgery Mode using the patient controller app or clinician programmer app. Confirm the neurostimulation system is functioning correctly after the procedure.

  • During implant procedures, if electrosurgery devices must be used, take the following actions:
  • Use bipolar electrosurgery only.
  • Complete any electrosurgery procedures before connecting the leads or extensions to the neurostimulator.
  • Keep the current paths from the electrosurgery device as far from the neurostimulation system as possible.
  • Set the electrosurgery device to the lowest possible energy setting.
  • Confirm that the neurostimulation system is functioning correctly during the implant procedure and before closing the neurostimulator pocket.

Implanted cardiac systems. Physicians need to be aware of the risk and possible interaction between a neurostimulation system and an implanted cardiac system, such as a pacemaker or defibrillator. Electrical pulses from a neurostimulation system may interact with the sensing operation of an implanted cardiac system, causing the cardiac system to respond inappropriately. To minimize or prevent the implanted cardiac system from sensing the output of the neurostimulation system, (1) maximize the distance between the implanted systems; (2) verify that the neurostimulation system is not interfering with the functions of the implanted cardiac system; and (3) avoid programming either device in a unipolar mode (using the device’s can as an anode) or using neurostimulation system settings that interfere with the function of the implantable cardiac system.

Security, antitheft, and radiofrequency identification (RFID) devices. Some antitheft devices, such as those used at entrances or exits of department stores, libraries, and other public places, and airport security screening devices may affect stimulation. Additionally, RFID devices, which are often used to read identification badges, as well as some tag deactivation devices, such as those used at payment counters at stores and loan desks at libraries, may also affect stimulation. Patients who are implanted with nonadjacent multiple leads and patients who are sensitive to low stimulation thresholds may experience a momentary increase in their perceived stimulation, which some patients have described as uncomfortable or jolting. Patients should cautiously approach such devices and should request help to bypass them. If they must go through a gate or doorway containing this type of device, patients should turn off their IPG and proceed with caution, being sure to move through the device quickly.

Motor vehicles, machinery, and equipment. Patients should not operate motor vehicles, potentially dangerous machinery, or power tools or engage in any activity that would be potentially unsafe if their symptoms were to return unexpectedly.

Device components. The use of components not approved for use by Abbott Medical with this system may result in damage to the system and increased risk to the patient.

Case damage. Do not handle the IPG if the case is pierced or ruptured because severe burns could result from exposure to battery chemicals.

Cremation. The IPG should be explanted before cremation because the IPG could explode. Return the explanted IPG to Abbott Medical.

IPG disposal. Return all explanted IPGs to Abbott Medical for safe disposal. IPGs contain batteries as well as other potentially hazardous materials. Do not crush, puncture, or burn the IPG because explosion or fire may result.

Charge density. A risk of tissue damage exists with stimulation parameter settings of high amplitudes and wide pulse widths. Higher amplitude and pulse width settings required to achieve therapy may indicate a system problem or suboptimal lead placement. Parameter values exceeding the charge density limit of 30 μC/cm2 should only be programmed with due consideration of the warnings concerning charge densities. Charge density can be reduced by lowering the stimulation amplitude or pulse width.

Low frequencies. Stimulation frequencies less than 30 Hz may be programmed; however, these frequencies may cause tremor to be driven (i.e., occur at the same frequency as the programmed frequency). For this reason, programming at lower frequencies is not recommended.

Precautions

The following precautions apply to this neurostimulation system.         

General Precautions

Surgeon training. Implanting physicians should be experienced in stereotactic and functional neurosurgery.

Clinician training. Clinicians should be familiar with deep brain stimulation therapy and be experienced in the diagnosis and treatment of the indication for which the deep brain stimulation components are being used.

Patient selection. Select patients appropriately for deep brain stimulation. The patient should be able and willing to use the patient controller and correctly interpret the icons and messages that appear on the screen.  

Infection. Follow proper infection control procedures. Infections may require that the device be explanted.

Electromagnetic interference (EMI). Some equipment in home, work, medical, and public environments can generate EMI that is strong enough to interfere with the operation of a neurostimulation system or damage system components. Patients should avoid getting too close to these types of EMI sources, which include the following examples: commercial electrical equipment (such as arc welders and induction furnaces), communication equipment (such as microwave transmitters and high-power amateur transmitters), high-voltage power lines, radiofrequency identification (RFID) devices, and some medical procedures (such as therapeutic radiation and electromagnetic lithotripsy).

Sterilization and Storage

Single-use, sterile device. The implanted components of this neurostimulation system are intended for a single use only. Sterile components in this kit have been sterilized using ethylene oxide (EtO) gas before shipment and are supplied in sterile packaging to permit direct introduction into the sterile field. Do not resterilize or reimplant an explanted system for any reason.

Storage environment. Store components and their packaging where they will not come in contact with liquids of any kind. Detailed information on storage environment is provided in the appendix of this manual.

Handling and Implantation

Expiration date. An expiration date (or “use-before” date) is printed on the packaging. Do not use the system if the use-before date has expired.

Care and handling of components. Use extreme care when handling system components prior to implantation. Excessive heat, excessive traction, excessive bending, excessive twisting, or the use of sharp instruments may damage and cause failure of the components.

Package or component damage. Do not implant a device if the sterile package or components show signs of damage, if the sterile seal is ruptured, or if contamination is suspected for any reason. Return any suspect components to Abbott Medical for evaluation.

System testing. To ensure correct operation, always test the system during the implant procedure, before closing the neurostimulator pocket, and before the patient leaves the surgery suite.

Device modification. The equipment is not serviceable by the customer. To prevent injury or damage to the system, do not modify the equipment. If needed, return the equipment to Abbott Medical for service.

 

Hospital and Medical Environments

Electrical medical treatment. In the case that a medical treatment is administered where an electrical current is passed through the body from an external source, first deactivate the IPG by setting all electrodes to off, turning stimulation off, and setting amplitude to zero. Regardless if the device is deactivated, take care to monitor the device for proper function during and after treatment.

High-output ultrasonics and lithotripsy. The use of high-output devices, such as an electrohydraulic lithotriptor, may cause damage to the electronic circuitry of an implanted IPG. If lithotripsy must be used, do not focus the energy near the IPG.

Ultrasonic scanning equipment. The use of ultrasonic scanning equipment may cause mechanical damage to an implanted neurostimulation system if used directly over the implanted system.

External defibrillators. The safety of discharge of an external defibrillator on patients with implanted neurostimulation systems has not been established.

Therapeutic radiation. Therapeutic radiation may damage the electronic circuitry of an implanted neurostimulation system, although no testing has been done and no definite information on radiation effects is available. Sources of therapeutic radiation include therapeutic X rays, cobalt machines, and linear accelerators. If radiation therapy is required, the area over the implanted IPG should be shielded with lead. Damage to the system may not be immediately detectable.

Psychotherapeutic procedures. The safety of psychotherapeutic procedures, such as electroshock therapy and transcranial magnetic stimulation, which use equipment that generates electromagnetic interference, has not been established.

Electrocardiograms. Neurostimulation pulses may be detected by electrocardiograms.

 

Home and Occupational Environments

Patient activities and environmental precautions. Patients should take reasonable care to avoid devices that generate strong EMI, which may cause the neurostimulation system to unintentionally turn on or off. Patients should also avoid any activities that would be potentially unsafe if their symptoms were to return unexpectedly.

Mobile phones. The effect of mobile phones on deep brain stimulation is unknown. Patients should be advised to avoid carrying mobile phones in their shirt pocket or otherwise placing them directly over the deep brain stimulation system components. If interference occurs, try holding the phone to the other ear or turning off the phone.

Household appliances. Household appliances that contain magnets (e.g., refrigerators, freezers, inductive cooktops, stereo speakers, mobile telephones, cordless telephones, standard wired telephones, AM/FM radios, and some power tools) may unintentionally cause the neurostimulation system to turn on or turn off.

Therapeutic magnets. Patients should be advised to not use therapeutic magnets. Therapeutic magnets (e.g., magnets used in pillows, mattress pads, back belts, knee braces, wrist bands, and insoles) may unintentionally cause the neurostimulation system to turn on or off.  

Radiofrequency sources. Devices that contain permanent magnets (e.g., mobile telephones, cordless telephones, standard wired telephones, and AM/FM radios) may unintentionally cause the IPG to turn on or off.

 

 Adverse Effects

Deep brain stimulation potentially has the following adverse effects:

Possible surgical complications. Surgical complications include, but are not limited to, the following: intracranial hemorrhage (which can lead to stroke, paralysis, or death); subcutaneous hemorrhage or seroma; hematoma; cerebrospinal fluid leakage or cerebrospinal fluid abnormality; brain contusion; infection or inflammation; antibiotic anaphylaxis; skin disorder; edema; persistent pain at surgery site or IPG site; erosion; brachial plexus injury (nerves to chest, shoulder and arm); postoperative pain, stress, or discomfort; neuropathy (nerve degeneration); hemiparesis (muscular weakness or partial paralysis on one side of body); ballism or hemiballism (uncontrollable movements on both or only one side of the body); confusion—transient, nocturnal or ongoing; cognitive impairment, including delirium, dementia, disorientation, psychosis and speech difficulties; aphasia; deep vein thrombosis; complications from anesthesia; phlebitis (vein inflammation); pulmonary embolism (sudden blood vessel obstruction); aborted procedures (air embolism, unable to find target, surgical complication, etc.); complications from unusual physiological variations in patients, including foreign body rejection phenomena; pneumonia, seizure or convulsions; paralysis (loss of motor function, inability to move); stroke and death.

Possible deep brain stimulation complications. Deep brain stimulation complications include, but are not limited to, the following:

  • Device-related complications

- Undesirable changes in stimulation related to cellular changes in tissue around the electrodes, changes in the electrode position, loose electrical connections, or lead fracture

- Loss of therapeutic benefit as a result of change in electrode positions, loose electrical connections, or lead or extension fracture

- Initial jolt or tingling during stimulation; jolting or shocking sensations

- Infection

- Paresthesia

- Lead fracture, migration, or dislodgement

- Misplaced lead

- Extension malfunction, fracture, or disconnect

- Deep brain stimulation system failure or battery failure within the device

- Deep brain stimulation system malfunction or dislodgement

- Spontaneous turning on or off of the IPG

- Allergic or rejection response to implanted materials

- Persistent pain, tightness, or redness at the incision sites or general pain

- General erosion or local skin erosion over the IPG

- Persistent pain, tightness, or discomfort around the implanted parts (e.g., along the extension path in the neck)  

- Impaired wound healing (e.g., incision site drainage) or abscess formation

- Additional neurosurgical procedure to manage one of the above complications or to replace a malfunctioning component

  •  Stimulation-related complications or other complications

- Worsening of motor impairment and Parkinson’s disease symptoms including dyskinesia, rigidity, akinesia or bradykinesia, myoclonus, motor fluctuations, abnormal gait or incoordination, ataxia, tremor, and dysphasia

- Paresis, asthenia, hemiplegia, or hemiparesis

- Dystonia

- Sensory disturbance or impairment including neuropathy, neuralgia, sensory deficit, headache, and hearing and visual disturbance

- Speech or language impairment including, aphasia, dysphagia, dysarthria, and hypophonia

- Cognitive impairment including attention deficit, confusion, disorientation, abnormal thinking, hallucinations, amnesia, delusions, dementia, inability to act or make decisions, psychic akinesia, long term memory impairment, psychiatric disturbances, depression, irritability or fatigue, mania or hypomania, psychosis, aggression, emotional lability, sleep disturbance, anxiety, apathy, drowsiness, alteration of mentation, postural instability and disequilibrium

- Restless leg syndrome

- Supranuclear gaze palsy

- Hypersexuality or increased libido

- Decreased therapeutic response

- Urinary incontinence or retention

- Diarrhea or constipation

- Cardiac dysfunction (e.g., hypotension, heart rate changes, or syncope)

- Difficulty breathing

- Increased salivation

- Weight gain or loss

- Eye disorder including eye apraxia or blepharospasm

- Nausea or vomiting

- Sweating

- Fever

- Hiccups

- Cough

- Cramps

- Worsening existing medical conditions  

- Hypersexuality or increased libido

- Decreased therapeutic response

- Urinary incontinence or retention

- Diarrhea or constipation

- Cardiac dysfunction (e.g., hypotension, heart rate changes, or syncope)

- Difficulty breathing

- Increased salivation

- Weight gain or loss  

- Eye disorder including eye apraxia or blepharospasm

- Nausea or vomiting

- Sweating

- Fever

- Hiccups

- Cough

- Cramps

- Worsening existing medical conditions

SJM-NWEB-0718-0142

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?

true
accessibility

© 2018 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. 

accessibility

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?